xtandi
(enzalutamide)Astellas Pharma US, Inc.
Usage: XTANDI® is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer (mCSPC), and non-metastatic castration-sensitive prostate cancer (nmCSPC) experiencing high-risk biochemical recurrence (high-risk BCR).